Document:

EX-4.2

Form of Registration Rights Agreement

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (the “Agreement”) is dated as of October 22, 2004
and is by and between TeraForce Technology Corporation, a Delaware corporation (the
“Company”) and [INVESTOR, a resident of Texas, (the “Investor”).

RECITALS

WHEREAS, as of an even date herewith, the Company and the Investor executed a Reimbursement
Agreement ( the “Reimbursement Agreement”); and

WHEREAS, pursuant to the Reimbursement Agreement, the Investor will acquire warrants for the
purchase of up to [ ] shares of the Company’s Common Stock, par value $.01 per share (“Common
Stock”) and shall have the right to acquire up to an additional [ ] shares of Common Stock upon
the exercise of Conversion Rights, as defined in the Reimbursement Agreement ( collectively the
“Shares”); and

WHEREAS, the parties desire to set forth the Investor’s rights and the Company’s obligations
to cause the registration of the Registrable Securities (as defined herein) pursuant to the
Securities Act (as defined herein);

NOW, THEREFORE, in consideration of the transactions contemplated by the Securities Purchase
Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:

Section 1. Definitions and Usage.

As used in this Agreement:

1.1 Definitions.

(a) “Blackout Period” shall have the meaning set forth in Section 3.

(b) “Business Day” shall mean any day except Saturday, Sunday and any day which shall
be a legal holiday or a day on which banking institutions in the state of New York generally are
authorized or required by law or other government actions to close.

(c) “Commission” shall mean the Securities and Exchange Commission.

(d) “Common Stock” shall mean (i) the common stock of the Company, par value $.01 per
share, and (ii) shares of capital stock of the Company issued by the Company in respect of or in
exchange for shares of such common stock in connection with any stock dividend or distribution,
stock split-up, recapitalization, recombination or exchange by the Company generally of shares of
such common stock.

(e) “Continuously Effective,” with respect to a specified registration statement,
shall mean that it shall not cease to be effective and available for Transfers of Registrable
Securities thereunder for longer than either (i) any ten (10) consecutive business days, or (ii) an
aggregate of fifteen (15) business days during the period specified in the relevant provision of
this Agreement.

(f) “Effectiveness Period” shall have the meaning set forth in Section 2.

(g) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

(h) “Filing Date” shall have the meaning set forth in Section 2.

(i) “Holders” shall mean the Investor and the transferees of the Registrable
Securities of the Investor, at such times as such Persons shall own Registrable Securities. For
purposes of this Agreement, a Person will be deemed to be a holder and an owner of Registrable
Securities whenever such Person has the right to acquire such Registrable Securities (by
conversion, purchase or otherwise), whether or not such acquisition has actually been effected and
whether or not such right is currently exercisable.

(j) “Person” shall mean any individual, sole proprietorship, partnership, limited
liability company, joint venture, trust, incorporated organization, association, corporation,
institution, public benefit corporation, entity or government (whether federal, state, county,
city, municipal or otherwise, including, without limitation, any instrumentality, division, agency,
body or department thereof).

(k) “Prospectus” means the prospectus included in the Registration Statement
(including, without limitation, a prospectus that includes any information previously omitted from
a prospectus filed as part of an effective registration statement in reliance upon Rule 430A
promulgated under the Securities Act), as amended or supplement by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by the
Registration Statement, and all other amendments and supplements to the Prospectus, including
post-effective amendments, and all material incorporated by reference or deemed to be incorporated
by reference in such Prospectus.

(l) “Register,” “registered,” and “registration” shall refer to a
registration effected by preparing and filing a registration statement or similar document in
compliance with the Securities Act, and the declaration or ordering by the Commission of
effectiveness of such registration statement or document.

(m) “Registrable Securities” shall mean the Shares; provided, however, that
Registrable Securities shall not include any Registrable Securities which have theretofore been
registered and sold pursuant to the Securities Act or which have been sold to the public pursuant
to Rule 144 or any similar rule promulgated by the Commission pursuant to the Securities Act, and,
provided further, the Company shall have no obligation under Section 2 or Section 3 to register any
Registrable Securities if the Company delivers to the Holders requesting such registration an
opinion of counsel to the effect that the proposed sale or disposition of all of the Registrable
Securities for which registration was requested does not require registration under the Securities
Act for a sale or disposition in a single public sale, and offers to remove any and all legends
restricting transfer from the certificates evidencing such Registrable Securities.

(n) “Registration Statement” means the registration statement and any additional
registration statements contemplated by Section 2 including (in each case) the Prospectus,
amendments and supplements to such registration statement or Prospectus, including pre- and
post-effective amendments, all exhibits thereto, and all material incorporated by reference or
deemed to be incorporated by reference in such registration statement.

(o) not used

(p) “Securities Act” shall mean the Securities Act of 1933, as amended.

(q) “Securities Purchase Agreement” shall have the meaning set forth in the Recitals
to this Agreement.

(r) “Transfer” shall mean and include the act of selling, giving, transferring,
creating a trust (voting or otherwise) and transferring title thereto, assigning or otherwise
disposing of (other than pledging, hypothecating or otherwise transferring as security) (and
correlative words shall have correlative meanings); provided however, that any transfer or other
disposition upon foreclosure or other exercise of remedies of a secured creditor after an event of
default under or with respect to a pledge, hypothecation or other transfer as security shall
constitute a “Transfer.”

(s) “Violation” shall have the meaning set forth in Section 6.

1.2 Usage.

(a) References to a Person are also references to its assigns and successors in interest (by
means of merger, consolidation or sale of all or substantially all the assets of such Person or
otherwise, as the case may be).

(b) References to Registrable Securities “owned” by a Holder shall include Registrable
Securities beneficially owned by such Person but which are held of record in the name of a nominee,
trustee, custodian, or other agent.

(c) References to a document are to a document as amended, waived and otherwise modified from
time to time and references to a statute or other governmental rule are to a statute or other
governmental rule as amended and otherwise modified from time to time (and references to any
provision thereof shall include references to any successor provision).

(d) References to Sections or to Schedules or Exhibits are to sections hereof or schedules or
exhibits hereto, unless the context otherwise requires.

(e) The definitions set forth herein are equally applicable both to the singular and plural
forms and the feminine, masculine and neuter forms of the terms defined.

(f) The term “including” and correlative terms shall be deemed to be followed by “without
limitation” whether or not followed by such words or words of like import.

(g) The term “hereof” and similar terms refer to this Agreement as a whole.

(h) The “date of” any notice or request given pursuant to this Agreement shall be determined
in accordance with Section 10.2.

Section 2. Shelf Registration. On or prior to December 31, 2004 (the “Filing
Date”), the Company shall prepare and file with the Commission a “Shelf” Registration Statement
covering all Registrable Securities for an offering to be made on a continuous basis pursuant to
Rule 415. The Registration Statement shall be on Form S-3 (if the Company is not then eligible to
register for resale the Registrable Securities on Form S-3 such registration shall be on another
appropriate form in accordance herewith). The Company shall use its best efforts to cause the
Registration Statement to be declared effective under the Securities Act as promptly as possible
after the filing thereof, and shall use its best efforts to keep such Registration Statement
Continuously Effective under the Securities Act until the date when all Registrable Securities
covered by such Registration Statement have been sold or may be sold without restrictions pursuant
to Rule 144(k) as determined by the counsel to the Company pursuant to a written opinion letter to
such effect, addressed and acceptable to the Company’s transfer agent (the “Effectiveness
Period”), provided, however, that the Company shall not be deemed to have used its best
efforts to keep the Registration Statement effective during the Effectiveness Period if it
voluntarily takes any action that would result in the Holder not being able to sell the Registrable
Securities covered by such Registration Statement during the Effectiveness Period, unless such
action is pursuant to a Blackout Period (as defined in Section 3) permitted hereunder, required
under applicable law or the Company has filed a post-effective amendment to the Registration
Statement and the Commission has not declared it effective. Other provisions of this Agreement
not withstanding, the Registration Statement may include shares of Common Stock held by other
holders or to be issued to other holders upon the exercise of warrants.

	 
	 

	Section 3.Registration Procedures.

	 

	 

	In connection with the Company’s registration obligations hereunder, the Company shall:

(a) Prepare and file with the Commission on or prior to the Filing Date, a Registration
Statement on Form S-3 (or if the Company is not then eligible to register for resale the
Registrable Securities on Form S-3 such registration shall be on another appropriate form in
accordance herewith) which shall contain the “Plan of Distribution” and cause the Registration
Statement to become effective and remain effective as provided herein; provided, however,
that not less than ten (10) Business Days prior to the filing of the Registration Statement or any
related Prospectus or any amendment or supplement thereto (including any document that would be
incorporated or deemed to be incorporated therein by reference), the Company shall (i) furnish to
the Holder copies of all such documents proposed to be filed, which documents (other than those
incorporated or deemed to be incorporated by reference) will be subject to the review and comment
of the Holder, and (ii) cause its officers and directors, counsel and independent certified public
accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of
respective counsel to the Holder, to conduct a reasonable investigation within the meaning of the
Securities Act. The Company shall not file the Registration Statement or any such Prospectus or
any amendments or supplements thereto to which the Investor shall reasonably object on a timely
basis.

(b) (i) Prepare and file with the Commission such amendments, including post-effective
amendments, to the Registration Statement as may be necessary to keep the Registration Statement
Continuously Effective as to the applicable Registrable Securities for the Effectiveness Period and
prepare and file with the Commission such additional Registration Statements in order to register
for resale under the Securities Act all of the Registrable Securities; (ii) cause the related
Prospectus to be amended or supplemented by any required Prospectus supplement, and as so
supplemented or amended to be filed pursuant to Rule 424 (or any similar provisions then in force)
promulgated under the Securities Act; (iii) respond as promptly as reasonably possible to any
comments received from the Commission with respect to the Registration Statement or any amendment
thereto and as promptly as reasonably possible provide the Holder true and complete copies of all
correspondence from and to the Commission relating to the Registration Statement; and (iv) comply
in all material respects with the provisions of the Securities Act and the Exchange Act with
respect to the disposition of all Registrable Securities covered by the Registration Statement
during the Effectiveness Period in accordance with the intended methods of disposition by the
Holder set forth in the Registration Statement as so amended or in such Prospectus as so
supplemented.

(c) Notify the Holder as promptly as reasonably possible (and, in the case of (i)(A) below,
not less than five (5) days prior to such filing) and (if requested by such Holder) confirm such
notice in writing no later than one (1) Business Day following the day (i)(A) when a Prospectus or
any Prospectus supplement or post-effective amendment to the Registration Statement is proposed to
be filed; (B) when the Commission notifies the Company whether there will be a “review” of such
Registration Statement and whenever the Commission comments in writing on such Registration
Statement (the Company shall provide true and complete copies thereof and all written responses
thereto to the Holder); and (C) with respect to the Registration Statement or any post-effective
amendment, when the same has become effective; (ii) of any request by the Commission or any other
Federal or state governmental authority for amendments or supplements to the Registration Statement
or Prospectus or for additional information; (iii) of the issuance by the Commission of any stop
order suspending the effectiveness of the Registration Statement covering any or all of the
Registrable Securities or the initiation of any proceedings for that purpose; (iv) if at any time
any of the representations and warranties of the Company contained in any agreement contemplated
hereby ceases to be true and correct in all material respects; (v) of the receipt by the Company of
any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation
or threatening of any proceeding for such purpose; and (vi) the occurrence of any event that makes
any statement made in the Registration Statement or Prospectus or any document incorporated or
deemed to be incorporated therein by reference untrue in any material respect or that requires any
revisions to the Registration Statement, Prospectus or other documents so that in the case of the
Registration Statement, it will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements therein
not misleading, and that in the case of the Prospectus or any Prospectus supplement, it will not
contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading.

(d) Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i)
any order suspending the effectiveness of the Registration Statement, or (ii) any suspension of the
qualification (or exemption from qualification) of any of the Registrable Securities for sale in
any jurisdiction, at the earliest practicable moment.

(e) Furnish to the Holder, without charge, at least one conformed copy of each Registration
Statement and each amendment thereto, including financial statements and schedules, all documents
incorporated or deemed to be incorporated therein by reference, and all exhibits to the extent
requested by such Holder (including those previously furnished or incorporated by reference)
promptly after the filing of such documents with the Commission.

(f) Promptly deliver to Holder, without charge, as many copies of the Prospectus or
Prospectuses (including each form of prospectus) and each amendment or supplement thereto as such
Holder may reasonably request; and the Company hereby consents to the use of such Prospectus and
each amendment or supplement thereto by the selling Holder in connection with the offering and sale
of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto.

(g) If the Registration Statement refers to the Holder by name or otherwise as the holder of
any securities of the Company, then such Holder shall have the right to require (if such reference
to such Holder by name or otherwise is not required by the Securities Act or any similar Federal
statute then in force) the deletion of the reference to such Holder in any amendment or supplement
to the Registration Statement filed or prepared subsequent to the time that such reference ceases
to be required.

(h) Holder covenants and agrees that (i) it will not sell any Registrable Securities under the
Registration Statement until it has received copies of the Prospectus as then amended or
supplemented as contemplated in Section 3(f) and notice from the Company that such Registration
Statement and any post-effective amendments thereto have become effective as contemplated by
Section 3(c)(i); and (ii) it and its officers, directors or affiliates, if any, will comply with
the prospectus delivery requirements of the Securities Act as applicable to it in connection with
sales of Registrable Securities pursuant to the Registration Statement.

(i) If there is a significant business opportunity (including but not limited to the
acquisition or disposition of assets (other than in the ordinary course of business) or any merger,
consolidation, tender offer or similar transaction) available to the Company which its Board of
Directors reasonably determines not to be in the Company’s best interest to disclose, then the
Company may suspend the right of the Holder to sell Registrable Securities under a Registration
Statement for one period not to exceed 20 Business Days during the Effectiveness Period (the
“Blackout Period”).

(j) Use all reasonable efforts to cause the Common Stock, if the Common Stock is then listed
on a securities exchange or included for quotation in a recognized trading market, to continue to
be so listed or included for a reasonable period of time after the offering.

(k) Use all reasonable efforts to cause the Registrable Securities covered by the Registration
Statement to be registered with or approved by such other United States or state governmental
agencies or authorities as may be necessary by virtue of the business and operations of the Company
to enable the selling Holders of Registrable Securities to consummate the disposition of such
Registrable Securities.

Section 4. Holders’ Obligations. It shall be a condition precedent to the obligations of
the Company to take any action pursuant to this Agreement with respect to the Registrable
Securities of any selling Holder of Registrable Securities that such selling Holder shall:

4.1 Furnish to the Company such information regarding such Selling Holder, the number of the
Registrable Securities owned by it, and the intended method of disposition of such securities as
shall be required to effect the registration of such selling Holder’s Registrable Securities, and
to cooperate with the Company in preparing such registration.

Section 5. Expenses of Registration.

5.1 The Company shall bear and pay all expenses and fees incurred in connection with the
Registration Statement pursuant to Section 2 for any Holder (which right may be Transferred to any
Person to whom Registrable Securities are Transferred as permitted by Section 7), including
registration, qualification and filing fees, exchange listing fees, printing expenses, escrow fees,
fees and disbursements of counsel for the Company, blue sky fees and expenses and the expenses of
any special audits incident to or required by any such registration, but excluding underwriting
discounts and commissions relating to Registrable Securities (which shall be paid by the Holders)
and fees and expenses of counsel to the Holder.

Section 6. Indemnification; Contribution. If any Registrable Securities are included in a
registration statement under this Agreement:

6.1 To the extent permitted by applicable law, the Company shall indemnify and hold harmless
each Holder, each Person, if any, who controls such Holder within the meaning of the Securities
Act, and each affiliate, officer, director, partner, agent and employee of such Holder and such
controlling Person, against any and all losses, claims, damages, liabilities and expenses (joint or
several), including attorneys’ fees and disbursements and expenses of investigation, incurred by
such party pursuant to any actual or threatened action, suit, proceeding or investigation, or to
which any of the foregoing Persons may become subject under the Securities Act, the Exchange Act or
other federal or state laws, insofar as such losses, claims, damages, liabilities and expenses
arise out of or are based upon any of the following statements, omissions or violations
(collectively a “Violation”):

(a) Any untrue statement or alleged untrue statement of a material fact contained in
the Registration Statement, including any preliminary Prospectus or final Prospectus
contained therein, or any amendments or supplements thereto;

(b) The omission or alleged omission to state therein a material fact required to be
stated therein, or necessary to make the statements therein not misleading; or

(c) Any violation or alleged violation by the Company of the Securities Act, the
Exchange Act, any applicable state securities law or any rule or regulation promulgated
under the Securities Act, the Exchange Act or any applicable state securities law;

provided, however, that the indemnification required by this Section 6.1 shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or expense if such settlement
is effected without the consent of the Company (which consent shall not be unreasonably withheld),
nor shall the Company be liable in any such case for any such loss, claim, damage, liability or
expense to the extent that it arises out of or is based upon a Violation that occurs in reliance
upon and in conformity with written information furnished to the Company by the indemnified party
expressly for use in connection with such registration; provided, further, that the indemnity
agreement contained in this Section 6 shall not apply to any Holder to the extent that any such
loss is based on or arises out of an untrue statement or alleged untrue statement of a material
fact, or an omission or alleged omission to state a material fact, contained in or omitted from any
preliminary prospectus if the final prospectus shall correct such untrue statement or alleged
untrue statement, or such omission or alleged omission, and a copy of the final prospectus has not
been sent or given to such person at or prior to the confirmation of sale to such person if such
Holder was under an obligation to deliver such final prospectus and failed to do so.

6.2 To the extent permitted by applicable law, each Holder, severally and not jointly, shall
indemnify and hold harmless the Company, each of its directors, each of its officers who shall have
signed the Registration Statement, and each Person, if any, who controls the Company within the
meaning of the Securities Act, against any and all losses, claims, damages, liabilities and
expenses, including attorneys’ fees and disbursements and expenses of investigation, incurred by
such party pursuant to any actual or threatened action, suit, proceeding or investigation, or to
which any of the foregoing Persons may otherwise become subject under the Securities Act, the
Exchange Act or other federal or state laws, insofar as such losses, claims, damages, liabilities
and expenses arise out of or are based upon any Violation, in each case to the extent (and only to
the extent) that such Violation occurs in reliance upon and in conformity with written information
furnished by such Holder expressly for use in connection with such registration; provided, however,
that the indemnification required by this Section 6.2 shall not apply to amounts paid in settlement
of any such loss, claim, damage, liability or expense if settlement is effected without the consent
of the relevant Holder of Registrable Securities, which consent shall not be unreasonably withheld.
Notwithstanding the foregoing, the liability of the Holder under this Section 6.2 shall be limited
in an amount equal to the net proceeds from the sale of the shares sold by such Holder, unless such
liability arises out of or is based on willful conduct or gross negligence by such Holder.

6.3 Promptly after receipt by an indemnified party under this Section 6 of notice of the
commencement of any action, suit, proceeding, investigation or threat thereof made in writing for
which such indemnified party may make a claim under this Section 6, such indemnified party shall
deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying
party shall have the right to participate in, and, to the extent the indemnifying party so desires,
jointly with any other indemnifying party similarly noticed, to assume the defense thereof with
counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall
have the right to retain its own counsel, with the fees and disbursements and expenses to be paid
by the indemnifying party, if representation of such indemnified party by the counsel retained by
the indemnifying party would be inappropriate due to actual or potential differing interests
between such indemnified party and any other party represented by such counsel in such proceeding.
The failure to deliver written notice to the indemnifying party within a reasonable time following
the commencement of any such action, if prejudicial to its ability to defend such action, shall
relieve such indemnifying party of any liability to the indemnified party under this Section 6 but
shall not relieve the indemnifying party of any liability that it may have to any indemnified party
otherwise than pursuant to this Section 6. Any fees and expenses incurred by the indemnified party
(including any fees and expenses incurred in connection with investigating or preparing to defend
such action or proceeding) shall be paid to the indemnified party, as incurred, within thirty (30)
days of written notice thereof to the indemnifying party (regardless of whether it is ultimately
determined that an indemnified party is not entitled to indemnification hereunder). Any such
indemnified party shall have the right to employ separate counsel in any such action, claim or
proceeding and to participate in the defense thereof, but the fees and expenses of such counsel
shall be the expenses of such indemnified party unless (i) the indemnifying party has agreed to pay
such fees and expenses or (ii) the indemnifying party shall have failed to promptly assume the
defense of such action, claim or proceeding or (iii) the named parties to any such action, claim or
proceeding (including any impleaded parties) include both such indemnified party and the
indemnifying party, and such indemnified party shall have been advised by counsel that there may be
one or more legal defenses available to it which are different from or in addition to those
available to the indemnifying party and that the assertion of such defenses would create a conflict
of interest such that counsel employed by the indemnifying party could not faithfully represent the
indemnified party (in which case, if such indemnified party notifies the indemnifying party in
writing that it elects to employ separate counsel at the expense of the indemnifying party, the
indemnifying party shall not have the right to assume the defense of such action, claim or
proceeding on behalf of such indemnified party, it being understood, however, that the indemnifying
party shall not, in connection with any one such action, claim or proceeding or separate but
substantially similar or related actions, claims or proceedings in the same jurisdiction arising
out of the same general allegations or circumstances, be liable for the reasonable fees and
expenses of more than one separate firm of attorneys (together with appropriate local counsel) at
any time for all such indemnified parties, unless in the reasonable judgment of such indemnified
party a conflict of interest may exist between such indemnified party and any other of such
indemnified parties with respect to such action, claim or proceeding, in which event the
indemnifying party shall be obligated to pay the fees and expenses of such additional counsel or
counsels). No indemnifying party shall be liable to an indemnified party for any settlement of any
action, proceeding or claim without the written consent of the indemnifying party, which consent
shall not be unreasonably withheld.

6.4 If the indemnification required by this Section 6 from the indemnifying party is
unavailable or insufficient to hold harmless an indemnified party hereunder in respect of any
losses, claims, damages, liabilities or expenses referred to in this Section 6:

(a) The indemnifying party, in lieu of indemnifying such indemnified party, shall
contribute to the amount paid or payable by such indemnified party as a result of such
losses, claims, damages, liabilities or expenses in such proportion as is appropriate to
reflect (i) the relative benefits received by the indemnifying party or parties, on the one
hand and the indemnified party on the other from the sale of the Registrable Securities, or
(ii) if the allocation provided by the foregoing clause (i) is not permitted by applicable
law, not only the relative benefits referred to in clause (i) above but also the relative
fault of the indemnifying party on the one hand and indemnified parties on the other in
connection with the actions which resulted in such losses, claims, damages, liabilities or
expenses, as well as any other relevant equitable considerations. The relative fault of such
indemnifying party and indemnified parties shall be determined by reference to, among other
things, whether any Violation has been committed by, or relates to information supplied by,
such indemnifying party or indemnified parties, and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such Violation. The amount paid
or payable by a party as a result of the losses, claims, damages, liabilities and expenses
referred to above shall be deemed to include, subject to the limitations set forth in
Section 6.1 and Section 6.2, any legal or other fees or expenses reasonably incurred by such
party in connection with any investigation or proceeding.

(b) The parties hereto agree that it would not be just and equitable if contribution
pursuant to this Section 6.4 were determined by pro rata allocation or by any other method
of allocation which does not take into account the equitable considerations referred to in
Section 6.4(a). No Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who
was not guilty of such fraudulent misrepresentation.

(c) Notwithstanding the provisions of this Section 6.4, a Holder shall not be required
to contribute any amount or make any other payments under this Agreement that in the
aggregate exceed the net proceeds received by the Holder from the sales of the Registrable
Securities of the Company.

6.5 The obligations of the Company and the selling Holders of Registrable Securities under
this Section 6 shall survive the completion of any offering of Registrable Securities pursuant to a
registration statement under this Agreement, and otherwise.

Section 7. Transfer of Registration Rights. The rights of a Holder hereunder may be
Transferred in whole or in part to (i) any affiliate (as defined in Rule 12b-2 under the Exchange
Act) of a Holder or (ii) any other Person upon the prior written consent of the Company; provided,
however, that any such transferee that is not a party to this Agreement shall have executed and
delivered to the Secretary of the Company a properly completed agreement substantially in the form
of Exhibit A, and provided, further, that the transferor shall have delivered to the
Secretary of the Company, no later than 15 days following the date of the Transfer, written
notification of such Transfer setting forth the name of the transferor, name and address of the
transferee and the number of Registrable Securities which shall have been so Transferred.

Section 8. Amendment, Modification and Waivers; Further Assurances.

(a) This Agreement may be amended with the consent of the parties hereto and the
Company may take any action herein prohibited, or omit to perform any act herein required to
be performed by it, only if the Company shall have obtained the written consent of the
Holder.

(b) No waiver of any terms or conditions of this Agreement shall operate as a waiver
of any other breach of such terms and conditions or any other term or condition, nor shall
any failure to enforce any provision hereof operate as a waiver of such provision or of any
other provision hereof. No written waiver hereunder, unless it by its own terms explicitly
provides to the contrary, shall be construed to effect a continuing waiver of the provisions
being waived and no such waiver in any instance shall constitute a waiver in any other
instance or for any other purpose or impair the right of the party against whom such waiver
is claimed in all other instances or for all other purposes to require full compliance with
such provision.

(c) Each of the parties hereto shall execute all such further instruments and documents
and take all such further action as any other party hereto may reasonably require in order
to effectuate the terms and purposes of this Agreement.

Section 9. Assignment; Benefit. This Agreement and all of the provisions hereof shall be
binding upon and shall inure to the benefit of the parties hereto and their respective heirs,
assigns, executors, administrators or successors; provided, however, that except as specifically
provided herein with respect to certain matters, neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned or delegated by the Company without the prior
written consent of the Holder. A Holder may Transfer its rights hereunder to a successor in
interest to the Registrable Securities owned by such assignor as permitted by Section 7.

Section 10. Miscellaneous.

10.1 Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF TEXAS, WITHOUT GIVING REGARD TO THE CONFLICT OF LAWS PRINCIPLES
THEREOF. EACH OF THE PARTIES HEREBY SUBMITS TO PERSONAL JURISDICTION AND WAIVES ANY OBJECTION AS TO
VENUE IN THE COUNTY OF DALLAS, STATE OF TEXAS. THE PARTIES HERETO WAIVE ALL RIGHT TO TRIAL BY JURY
IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT.

10.2 Notices. All notices and other communications required or permitted hereunder
shall be in writing and shall be deemed to have been sufficiently given (a) if sent by facsimile
transmission, upon telephonic confirmation of receipt, (b) if sent by registered or certified mail,
upon the sooner of the expiration of five (5) days after deposit in the post office facilities
properly addressed with postage prepaid or acknowledgment of receipt, (c) if personally delivered,
when delivered to the party to whom notice is sent, or (d) if delivered by a recognized overnight
courier, upon receipt evidencing proof of delivery, addressed to the appropriate party or parties,
at the address of such party set forth below, (or at such other address as such party may designate
by written notice furnished to all other parties in accordance herewith):

(a) if to the Investor:

(b) if to the Company:

TeraForce Technology Corporation

1240 E. Campbell Road

Richardson, TX 75081

(469) 330-4951

(469) 330-4972 fax

Attn: Robert P. Capps

10.3 Entire Agreement; Integration. This Agreement supersedes all prior agreements
between or among any of the parties hereto with respect to the subject matter contained herein, and
this Agreement embodies the entire understanding among the parties relating to such subject matter.

10.4 Section Headings. Section headings are for convenience of reference only and
shall not affect the meaning of any provision of this Agreement.

10.5 Counterparts. This Agreement may be executed in any number of counterparts, each
of which shall be an original, and all of which shall together constitute one and the same
instrument. All signatures need not be on the same counterpart.

10.6 Severability. If any provision of this Agreement shall be invalid or
unenforceable, such invalidity or unenforceability shall not affect the validity and enforceability
of the remaining provisions of this Agreement, unless the result thereof would be unreasonable, in
which case the parties hereto shall negotiate in good faith as to appropriate amendments hereto.

10.7 Filing. A copy of this Agreement and of all amendments thereto shall be filed at
the principal executive office of the Company with the corporate recorder of the Company.

10.8 Termination. This Agreement may be terminated at any time by a written
instrument signed by the parties hereto. Unless sooner terminated in accordance with the preceding
sentence, this Agreement (other than Section 6 hereof) shall terminate in its entirety on such date
as there shall be no Registrable Securities outstanding or issuable by the Company.

10.9 No Third Party Beneficiaries. Nothing herein expressed or implied is intended to
confer upon any Person, other than the parties hereto or their respective permitted assigns,
successors, heirs and legal representatives, any rights, remedies, obligations or liabilities under
or by reason of this Agreement.

1

IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the date
first written above.

TERAFORCE TECHNOLOGY CORPORATION

By:

Name: Robert P. Capps

Title: Executive Vice President

Investor

2EX-10..1

REIMBURSEMENT AGREEMENT

by and among

DNA COMPUTING SOLUTIONS, INC.

TERAFORCE TECHNOLOGY CORPORATION

and

Richard E. Bean

Robert E. Garrison II

Steven A. Webster

James Hawkins

Peter Badger

John Styles

Donald Campbell

Dated as of October 22, 2004

1

REIMBURSEMENT AGREEMENT

This REIMBURSEMENT AGREEMENT dated as of October 22, 2004, (the “Agreement), is made by and
between TERAFORCE TECHNOLOGY CORPORATION, a Delaware corporation ( “TERA”), DNA COMPUTING
SOLUTIONS, INC, a Delaware corporation and a wholly-owned subsidiary of TERA (“DNA-CS”) (TERA and
DNA-CS collectively referred to as the Companies) and Richard E. Bean, an individual residing in
Texas, Robert E. Garrison II, an individual residing in Texas, Steven A. Webster, an individual
residing in Texas, James Hawkins, an individual residing in Texas, Peter Badger, an individual
residing in Texas, Donald Campbell, an individual residing in Texas, and John Styles, an individual
residing in Texas ( each individual a “Guarantor” and collectively the “Guarantors”) (the TERA,
DNA-CS and Guarantors collectively referred to as the “Parties”)

W I T N E S S E T H:

WHEREAS, the Companies contemplate entering into a loan agreement with First Capital Bank (the
“Bank”) providing for the loan of up to $600,000 to DNA-CS (the “October Loan Agreement”) ; and

WHEREAS, the Companies previously entered into a loan agreement with the Bank dated July 30,
2004 providing for the loan of up to $575,000 to DNA-CS (the “July Loan Agreement”); and

WHEREAS, in order to enter into the July Loan Agreement the bank required the Guarantors to
provide limited guarantees aggregating $776,250 and the Guarantors provided these limited
guarantees pursuant to a Reimbursement Agreement dated July 27, 2004 among the Parties; and,

WHEREAS, DNA-CS have granted the Bank a security interest in certain assets, including
accounts receivable, fixed assets and inventories; and

WEREAS, in order to enter into the October Loan Agreement the Bank has required the Guarantors
to provide limited guarantees aggregating $810,000; and

WHEREAS, in order to induce the Bank to enter into the October Loan Agreement, each Guarantor
has executed a limited guarantee to secure the loan there under in the amount as indicated in
Schedule I ( the “Guarantee”); and

WHEREAS, the Bank shall provide Advances (as hereinafter defined) to the DNA-CS in accordance
with the provisions of the October Loan Agreement and shall be entitled to make demand upon the
Guarantors pursuant to the provisions of the Guarantees in the case of an Event of Default (as
defined in the October Loan Agreement) by the Companies under the October Loan Agreement; and

NOW, THEREFORE, in consideration of the foregoing, the Companies and the Guarantors covenant
and agree as follows:

ARTICLE I

GENERAL TERMS

Section 1.1. Definitions. As used in this Agreement, the following terms shall have
the following meanings:

“Advances” shall mean an advance of funds under and subject to the terms and conditions of the
October Loan Agreement provided that the principal amount outstanding shall never exceed the Loan
Maximum.

“Agreement” shall have the meaning specified in the preamble.

“Associated Expenses” shall mean the expenses associated with recovering the Guarantor
Advances, excluding the Guarantor Advances and interest thereon.

“Bank” shall have the meaning set forth in the recitals.

“Common Stock” shall mean the common stock, par value $0.01, of TERA.

“Demand for Reimbursement” shall have the meaning specified in Section 3.2(a).

“Governmental Authority” means any United States or foreign federal, territorial, state or
local governmental authority, quasi-governmental authority, instrumentality, court, government or
self-regulatory organization, commission, tribunal or organization or any regulatory,
administrative or other agency, or any political or other subdivision, department or branch of any
of the foregoing.

“Guarantor Advance” shall mean the amount of money advanced by the Guarantor to the Bank
pursuant to a demand for payment by the Bank on the Guarantee.

“Guarantor” and “Guarantors” shall have the meanings specified in the preamble.

“Guarantee” shall have the meaning set forth in the recitals.

“Guarantor’s Percentage ” shall mean the amount of a Guarantor’s Guarantee divided by the
aggregate amount of Guarantees provided by the Guarantors.

“Loans” shall mean the Companies’ obligations pursuant to the October Loan Agreement and the
July Loan Agreement.

“Loan Documents” shall mean the October Loan Agreement and all exhibits and related documents
thereto, as they may be amended, extended or modified from time to time, including, without
limitation, a promissory note.

“Loan Maximum” shall mean the principal amounts outstanding of $600,000.

“Person” means an individual, corporation, partnership, association, limited liability
company, trust, estate or other similar business entity or organization, including a Governmental
Authority.

“Registration Rights Agreement” shall have the meaning specified in Section 4.3.

“Reimbursement Obligation” shall have the meaning specified in Section 3.2(a).

“Related Documents” shall mean the Warrants and the Registration Rights Agreement.

“Warrants” shall have the meaning specified in Section 4.1.

Section 1.2. Interpretation.

(a) In this Agreement:

(i) the singular number includes the plural number and vice versa;

(ii) reference to any gender includes each other gender;

(iii) the words “herein,” “hereof” and “hereunder” and other words of similar import refer to
this Agreement as a whole and not to any particular Article, Section or other subdivision;

(iv) reference to any Person includes such Person’s heirs, administrators, successors and
assigns but, if applicable, only if such heirs, administrators, successors and assigns are
permitted by this Agreement, and reference to a Person in a particular capacity excludes such
Person in any other capacity or individually, provided that nothing in this sub clause (iv) is
intended to authorize any assignment not otherwise permitted by this Agreement;

(v) reference to any agreement, document or instrument means such agreement, document or
instrument as amended, supplemented or modified and in effect from time to time in accordance with
the terms thereof and, if applicable, the terms hereof, and reference to the Note includes any Note
issued pursuant hereto in extension or renewal hereof and in substitution or replacement here for;

(vi) unless the context indicates otherwise, reference to any Article, Section, Schedule or
Exhibit means such Article or Section hereof or such Schedule or Exhibit hereto;

(vii) the words “including” (and with correlative meaning “include”) means including, without
limiting the generality of any description preceding such term;

(viii) with respect to the determination of any period of time, the word “from” means “from
and including” and the word “to” means “to, but excluding”;

(ix) reference to any law means such as amended, modified, codified or reenacted, in whole or
in part, and in effect from time to time; and

(b) No provision of this Agreement shall be interpreted or construed against any Person solely
because that Person or its legal representative drafted such provision.

ARTICLE II

THE GUARANTIES

Section 2.1 Guarantees. On the terms and subject to the terms hereof, each
Guarantor agrees to provide the Guarantee in the amount as indicated on Schedule I in substantially
the form as in Exhibit A.

ARTICLE III

ASSUMPTION OF LOAN, REIMBURSEMENT

Section 3.1 Assumption of Loan. Should the Guarantors be required to make payment
to the Bank pursuant to the Guarantee, the Companies hereby consent to the assumption of the
October Loan Agreement the Guarantors, including all collateral rights. The Companies will use
their best efforts to facilitate such assumption.

Section 3.2. Reimbursable Amounts and Other Payments

(a) Amounts. Should the Guarantors not elect to, or be unable for any reason to,
assume the October Loan Agreement, the Companies shall reimburse each Guarantor the amount paid by
the Guarantor to the Bank equal to the amount of his Guarantor Advance and any interest, taxes,
fees, charges or other costs and expenses incurred by Guarantor in connection with such payment
(the “Reimbursement Obligation”). Each such Reimbursement Obligation shall be paid by the
Companies to Guarantor promptly upon written demand from Guarantor (“Demand for Reimbursement”),
but in no event later than thirty (30) days after such demand. Each such Demand for
Reimbursement, in order to be valid, shall be accompanied by sufficient documentation, such as
copies of documents provided by the Bank to the Guarantors, supporting the amount of the
Reimbursement Obligation.

(b) Interest. The Company shall pay interest on any and all amounts remaining unpaid
under Section 3.1(a) at any time from the date such amounts become payable until paid in full,
payable on demand, at simple interest at the prime rate established by Bank One, N.A., plus 2.0%
per annum (or, if less, the highest rate permitted under applicable law). The Guarantors may, at
their election, receive interest payments in shares of Common Stock. The number of shares of
Common Stock to be issued shall be determined by dividing the amount of the interest payment by
$0.18.

(c) Currency. All payments by the Company to Guarantor shall be made in lawful
currency of the United States of America and in immediately available funds at, and pursuant to,
such instructions as Guarantor may from time to time give.

Section 3.2. Obligations Absolute.

(a) The DNA-CS’s obligations under this Article III shall be absolute and unconditional
irrespective of any set-off, counterclaim, or defense to payment which the Company may have or have
had against the Bank.

(b) The DNA-CS hereby agrees that Guarantor shall not be responsible for, and the
Reimbursement Obligations shall not be affected by, among other things,

(i) the validity or genuineness of documents or of any endorsements
thereon even though such documents shall prove to be invalid, fraudulent, or
forged;

(ii) any dispute between the DNA-CS, TERA and the Bank; or

(iii) any claims whatsoever of the DNA-CS or TERA against the Bank.

(c) Guarantor shall not be liable for any error, omission, interruption or delay in
transmission, dispatch or delivery of any message or advice, howsoever transmitted, in connection
with the Guaranty, except for errors or omissions caused by Guarantor’s primary negligence or
willful misconduct.

(d) The Companies agrees that any action taken or omitted by the Guarantor in connection
with the Guaranty, provided Guarantor’s actions are not the result of Guarantor’s primary
negligence, willful misconduct, or breach of contractual obligations, shall be binding on the
DNA-CS and TERA and shall not result in any liability to Guarantor.

Section 3.3 Indemnity In addition to the rights and obligations set forth in
Section 3.2(a), the Companies hereby agrees to indemnify and hold harmless Guarantor, and each of
his respective successors, heirs and assigns, from and against any and all claims and damages,
losses, liabilities, costs or expenses (including reasonable attorneys fees) which Guarantor may
incur by reason of or in connection with the issuance, execution and delivery or transfer or
payment or failure to pay the Guarantee except to the extent of the primary negligence or willful
misconduct of Guarantor, or as may be attributable to Guarantor’s breach of his obligations under
this Agreement.

Section 3.4 Agreement Among Guarantors Upon the Bank invoking any or all of the
Guarantees, each Guarantor shall fund an amount equal to the total amount of payments made to the
Bank times his Guarantor’s Percentage. Should any Guarantor’s Guarantor Advance be in excess of
this amount, the other Guarantors shall reimburse that Guarantor such that each Guarantor Advance
is proportionate to each Guarantor’s Percentage. Such reimbursement shall be made within 30 days
of a demand from another Guarantor

ARTICLE IV

CONVERSION RIGHTS AND WARRANTS

Section 4.1. Warrants. As an inducement to enter into this Agreement, TERA agrees
to issue to the Guarantors Warrants to purchase an aggregate of 6,666,667 shares of Common Stock at
an exercise price per share of $0.20, the form of which is attached as Exhibit B (the “Warrants”).
Each Guarantor shall receive Warrants to purchase a number of shares of Common Stock equal to the
aggregate number of Warrants times his Guarantor’s Percentage.

Section 4.2 Conversion Rights. As long as any Loans are outstanding or DNA-CS is
able to incur Loans under the October Loan Agreement, each Guarantor shall have the right to
purchase a number of shares of Common Stock equal to his proportionate share of the Loan Maximum
divided by $0.18. Proceeds from the issuance of such shares of Common Stock shall be utilized by
TERA to repay amounts outstanding under the October Loan Agreement and cause the Bank to release
Guarantees underlying the amount of the Loan repaid. The Companies will undertake such procedures
to ensure the Guarantor that the Guarantee will be released immediately upon the purchase of the
shares of Common Stock. Further, each Guarantor shall have the right to covert any Reimbursement
Obligation into a number of shares of Common Stock equal to the amount of the Reimbursement
Obligation divided by $0.18. The Companies shall give the Guarantors not less than 30 days notice
of the intent to repay the Loans and obtain the release of the Guarantees.

Section 4.3. Registration Rights. The TERA further agrees to grant the registration
rights to register the resale of the shares of Common Stock to be issued pursuant to the
Conversion Rights and the Warrants and the in accordance with the Registration Rights Agreement
attached hereto as Exhibit C (the “Registration Rights Agreement”).

Section 4.4. Subsequent Financings. Should TERA, at any time while the Guarantees
are outstanding, issue Common Stock at a price per share less than $0.18, or issue warrants or
convertible securities that provide for an exercise or conversion price of less than $0.18 per
share, then the conversion rate in Section 4.2 and the Warrant exercise price in Sections 4.1 above
shall be reduced to such lesser amount and the exercise price of the warrants shall be reduced to
such lesser amount.

Section 4.5 Sharing of Consideration. Should any Guarantor be required to make a
Guarantor Advance in an amount in excess of an amount equal to the Loan Maximum times his
Guarantor’s Percentage and does not receive reimbursement from the other Guarantors pursuant to
Section 3.4 of this Agreement and within the time frame required by Section 3.4, that Guarantor
shall receive additional Warrants and Conversion Rights proportionate with the amount of such
excess funding. Any Guarantor not making reimbursement to other Guarantors pursuant to Section 3.4
of this Agreement shall forfeit Warrants and Conversion Rights proportionate to the amount of
reimbursement not made.

2

ARTICLE V

REPRESENTATIONS AND WARRANTIES

Section 5.1. Representations and Warrants of the TERA and DNA-CS. TERA and DNA-CS
hereby represents and warrants to Guarantors as follows:

(a) Corporate Existence and Good Standing. Each is a corporation duly incorporated,
validly existing and in good standing under the laws of the State of Delaware and has all requisite
corporate power and authority to own its property and carry on its business as now conducted, and
is in good standing and authorized to do business in each jurisdiction in which the it owns real
property or conducts such business, where the failure to maintain such good standing or
authorization is reasonably expected to have a materially adverse effect on its business,
operations or financial or other condition, or could materially adversely affect its ability to
perform its obligations under this Agreement.

(b) Authorization and Validity. This Agreement and Related Documents have been duly
authorized by all necessary corporate action, and each has been duly executed and delivered by TERA
and DNA-CS and each is valid, binding and enforceable against the TERA and DNA-CS in accordance
with its terms except as may be limited by bankruptcy or insolvency laws and similar laws affecting
creditor rights generally and by generally and by general principles of equity.

(c) No Conflict; Government Consent; Title to Assets; No Liens. Neither the execution
and delivery of this Agreement and Related Documents, nor the consummation of the transactions
contemplated hereby or thereby nor compliance with the terms hereof or thereof under the
circumstances contemplated hereby or thereby will conflict with, are prohibited by or will
contravene, violate or constitute a breach of or a default under the Amended and Restated
Certificate of Incorporation or By-Laws of TERA or DNA-CS or constitute on the part of the TERA or
DNA-CS a material breach of or a material default under any agreement or other instrument to which
the either company is a party or any existing law, administrative regulation, or, to its knowledge,
any court order or consent decree to which TERA or DNA-CS is subject, or by which any of its
properties is bound.

5.2 Representations of Guarantors. Each Guarantor represents and warrants to the
TERA and DNA-CS that he has full power and authority to execute and deliver this Agreement and the
Related Documents, and that this Agreement and Related Documents are valid, binding and enforceable
in accordance with their terms as they relate to such Guarantor, except as may be limited by
bankruptcy and insolvency laws, and similar laws affecting creditors rights generally and by
general principals of equity. Each Guarantor represents and warrants that he or she (a) has such
knowledge and experience in financial and business matters that such Guarantor is capable of
evaluating the merits and risks of his or her investment and has the financial ability to assume
the monetary risk associated therewith; (b) is able to bear the complete loss of his or her
investment; (c) has received such documents and information from the TERA or DNA-CS as such
Guarantor has requested and has had the opportunity to ask questions of, and receive answers from,
the TERA and DNA-CS and the terms and conditions of the offering of the Warrants and the Common
Stock to be issued pursuant to the Conversion Rights and the Warrants and to obtain additional
information; (d) is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated
under the 1933 Act; and (e) is not relying upon any statements or instruments made or issued by any
person other than the TERA or DNA-CS in making a decision to invest in the Shares.

ARTICLE VI

AFFIRMATIVE AND NEGATIVE COVENANTS

Section 6.1 Conduct of Business. The TERA and DNA-CS covenant and agree that each
shall remain duly incorporated, validly existing and in good standing as a domestic corporation in
the State of Delaware, will not voluntarily dissolve without first discharging its obligations
under this Agreement.

Section 6.2 Limitation on Borrowings. TERA and DNA-CS covenant and agree that amount
of the Loans shall not exceed an amount equal to the sum of (a) the sum of the amount of DNA-CS
inventories and fixed assets each multiplied by 50% and (b) the amount of DNA-CS accounts
receivable multiplied by 80%. On a monthly basis the Companies will provide to the Guarantors, or
their designee, an officer’s certificate as to compliance with this Section 6.2.

Section 6.3 Pledge of Assets. The Companies will not pledge any assets, other than in
relation to the October Loan Agreement and the July Loan Agreement, without the express written
consent of the Guarantors.

ARTICLE VII

COVENANTS

Section 7.1 Successors and Assigns. This Agreement shall be binding upon each party
and their respective successors, heirs and assigns.

Section 7.2. Notices. All notices, requests and demands to or upon the respective
parties shall be in writing (including by facsimile) and, unless otherwise expressly provided
herein, shall be deemed to have been duly given or made (a) in the case of delivery by hand, when
delivered, (b) in the case of delivery by mail, three (3) days after being deposited in the mails,
postage prepaid, or (c) in the case of delivery by facsimile, when sent and receipt has been
confirmed, addressed as follows:

	 	 	 
	If to Guarantors:

	 	to the addresses as indicated on Schedule I
	 
	 	 
	If to the Company:

	 	TeraForce Technology Corporation

Attn.: Herman M. Frietsch, Chairman & CEO

1240 East Campbell Road

Richardson, Texas 75081

Telecopier: (469) 330-4999

Any entity entitled to receive notice hereunder may, by notice given hereunder, designate any
further or different addresses to which subsequent notices, certificates or other communications
shall be sent.

Section 7.3. Amendment. This Agreement may be amended, modified or discharged only
upon an agreement in writing of TERA, DNA-CS and each of the Guarantors.

Section 7.4. Effect of Delay and Waivers. No delay or omission to exercise any right
or power accruing upon any default, omission or failure of performance hereunder shall impair any
such right or power or shall be construed to be a waiver thereof, but any such right and power may
be exercised from time to time and as often as may be deemed expedient. In order to entitle
Guarantors to exercise any remedy now or hereafter existing at law or in equity or by statute, it
shall not be necessary to give any notice, other than such notice as may be herein expressly
required. In the event any provision contained in this Agreement should be breached by any party
and thereafter waived by the other party so empowered to act, such waiver shall be limited to the
particular breach so waived and shall not be deemed to waive any other breach hereunder. No
waiver, amendment, release or modification of this Agreement shall be established by conduct,
custom or course of dealing, but solely by an instrument in writing duly executed by the parties
thereunto duly authorized by this Agreement.

Section 7.5. Counterparts. This Agreement may be executed simultaneously in
counterparts, each of which shall be deemed an original, but both of which together shall
constitute one and the same instrument.

Section 7.6. Severability. The invalidity or unenforceability of any one or more
phrases, sentences, clauses or Sections contained in this Agreement shall not affect the validity
or enforceability of the remaining portions of this Agreement, or any part thereof. In particular,
this section means (among other things) that TERA and DNA-CS do not agree or intend to pay, and
Guarantors do not agree to contract for, charge, collect, take, reserve or receive (collectively
referred to herein as “charge or collect”), any amount in the nature of interest or in the nature
of a fee for anything construed to be a loan, which would in any way or event (including demand,
prepayment, or acceleration) cause Guarantors to charge or collect more for entering into this
Agreement than the maximum amount Guarantors would be permitted to charge or collect by federal law
or the laws of the State of Texas. Any such excess interest or unauthorized fee shall, instead or
anything stated to the contrary, be applied first to reduce the principal balance of the loan, if
any, and when the principal has been paid in full, refunded to the Companies.

Section 7.7. Governing Law and Jurisdiction. This Agreement shall be governed by and
construed in accordance with the laws of the State of Texas.

3

This Agreement has been signed by the Company as of the date first above written.

TERA:

TeraForce Technology Corporation

By:/s/ Robert P. Capps

	 	 	 	Robert P. Capps, Executive Vice President

DNA-CS:

DNA Computing Solutions, Inc.

By: /s/ Robert P. Capps 

	 	 	 	Robert P. Capps, Executive Vice President

GUARANTORS:

/s/ Richard E. Bean 

	 	 	 	Richard E. Bean

/s/ Robert E. Garrison II

Robert E. Garrison II

/s/ Steven A. Webster

	 	 	 	Steven A. Webster

/s/ James Hawkins

	 	 	 	James Hawkins

/s/ Peter Badger

	 	 	 	Peter Badger

/s/ John Styles

	 	 	 	John Styles

/s/ Donald Campbell

	 	 	 	Donald Campbell

4

Schedule I

Guarantors

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Proportionate

	 
	 	 	 	 	 	Limit of	 	Guarantor’s            
	 	 	 	 	 	Share of
	Name
	 	Address	 	Guarantee	 	Percentage             
	 	Warrants             
	 	Loan Maximum

	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	P.O. Box 35068
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Houston, TX  77235
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Richard E. Bean
	 	Fax: (713) 551-0427              
	 	$	148,500		 	 	18.33	%	 	 	1,222,223	 	 	$	110,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	600 Travis	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Suite 3000
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Robert E. Garrison
	 	Houston, TX  77030
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	II
	 	Fax: (713) 993-4677              
	 	$	148,500	 	 	 	18.33	%	 	 	1,222,222	 	 	$	110,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	14701 St.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Mary’s Lane Suite
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 		800		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Houston, Texas  77079
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Steven A. Webster
	 	Fax:  (281) 558-3011             
	 	$	148,500		 	 	18.33	%	 	 	1,222,222	 	 	$	110,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	P.O. Box 8216	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Waco, TX  76714	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	James Hawkins
	 	Fax:  (254) 761-2951             
	 	$	148,500	 	 	 	18.33	%	 	 	1,222,222	 	 	$	110,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	600 Travis	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Suite 3100	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Houston, TX  77030	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Peter Badger
	 	Fax:  (713) 993-4606             
	 	$	148,500	 	 	 	18.33	%	 	 	1,222,222	 	 	$	110,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	2200 Southwest Frwy	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Suite 500	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Houston, TX  77098	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	John Styles
	 	Fax:  (713) 383-9549             
	 	$	33,750	 	 	 	4.17	%	 	 	277,778	 	 	$	25,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	323 Tamerlaine	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Houston, TX  77024	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Donald Campbell
	 	Fax:  (713) 827-1191             
	 	$	33,750	 	 	 	4.17	%	 	 	277,778	 	 	$	25,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]